WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2016105516) METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2016/105516    International Application No.:    PCT/US2015/000269
Publication Date: 30.06.2016 International Filing Date: 23.12.2015
IPC:
A61K 48/00 (2006.01)
Applicants: CELGENE CORPORATION [US/US]; 86 Morris Avenue Summit, NJ 07901 (US) (US only).
CELGENE ALPINE INVESTMENT COMPANY II, LLC [US/--]; AON House, 30 Woodbourne Avenue Pembroke, HM 08 (BM) (For All Designated States Except US)
Inventors: SMITH, Scott Andrew; (US).
LI, Xiaobin; (US).
ROSSITER, Guillermo; (US).
MARTIN, Philippe L.; (US).
DEWACKER, Seth R.; (US).
USISKIN, Keith; (US).
CLINE, Gary Allan; (US)
Agent: MARTINEK, Sebastian; (US)
Priority Data:
62/097,012 26.12.2014 US
62/235,269 30.09.2015 US
Title (EN) METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES
(FR) MÉTHODES D'UTILISATION D'OLIGONUCLÉOTIDES ANTISENS CIBLANT SMAD7
Abstract: front page image
(EN)Described herein are methods of treating inflammatory bowel disease (I BD) in a patient having IBD using SMAD7 antisense oligonucleotides. In one aspect, provided herein is a method for treating or managing inflammatory bowel disease (IBD) in a patient having IBD, wherein the method comprises (a) administering to the patient a SMAD7 antisense-oligonucleotide (SMAD7 AON) during a first treatment period at a first dose; and (b) administering to the patient the SMAD7 antisense-oligonucleotide during a second treatment period at a second dose.
(FR)L'invention concerne des méthodes de traitement de la maladie inflammatoire chronique de l'intestin (MICI) chez le patient souffrant d'une MICI à l'aide d'oligonucléotides antisens ciblant SMAD7. Dans un aspect, l'invention concerne une méthode destinée à traiter ou gérer une maladie inflammatoire chronique de l'intestin (MICI) chez le patient souffrant de MICI, la méthode comprenant (a) l'administration au patient d'un oligonucléotide antisens ciblant SMAD7 (ODN SMAD7) pendant une première période de traitement, à une première dose ; et b) l'administration au patient de l'oligonucléotide antisens ciblant SMAD7 pendant une deuxième période de traitement, à une seconde dose.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)